← Eichor
Condition: Allogenic Transplant Patients Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Allogenic Transplant Patients

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Intraoral Photobiomodulation Therapy to Prevent Oral Mucositis in Patients Undergoing Hematopoietic Cell Transplantation
NA · 1 location(s) · Dana-Farber Cancer Institute · NCT05335434Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administ
Phase 1/Phase 2 · 8 location(s) · SNIPR Biome Aps. · NCT06938867Evaluate the Safety and Therapeutic Effects of a Single Intravenous Infusion (IV) of Autologous CD34+ Cells Enriched Wit
Phase 2 · 1 location(s) · Minovia Therapeutics Ltd. · NCT06017869Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML
Phase N/A · 1 location(s) · Peking University People's Hospital · NCT07500441Molecular Mechanisms of Disease Relapse After Allogenic Stem Cell Transplantation in MDS Patients
NA · 7 location(s) · Gruppo Italiano Malattie EMatologiche dell'Adulto · NCT04587856Evaluation of the Safety and Efficacy of LB-DTK-MV in Patients Diagnosed With Antiviral-Resistant CMV, BKV, or EBV Infec
Phase 1/Phase 2 · 1 location(s) · LucasBio · NCT07670468Momelotinib During and After HCT in Myelofibrosis
Phase 1 · 1 location(s) · Massachusetts General Hospital · NCT07104799Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT
Phase 1 · 1 location(s) · Stanford University · NCT06551584Sustained Oral Fiber Supplementation for Patients Undergoing Donor Stem Cell Transplantation for Hematological Malignanc
NA · 1 location(s) · Fred Hutchinson Cancer Center · NCT04829136CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic Diseases
Phase 1/Phase 2 · 1 location(s) · Zhejiang University · NCT05827835Prophylactic TCRaB+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Pati
NA · 1 location(s) · University of Wisconsin, Madison · NCT07285668Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation
Phase 2 · 2 location(s) · City of Hope Medical Center · NCT03728335Efficacy and Safety of Lusutrombopag After Allogeneic Hematopoietic Stem Cell Transplantation
NA · 1 location(s) · The General Hospital of Western Theater Command · NCT07483385Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing
Phase N/A · 1 location(s) · National Cancer Institute (NCI) · NCT06856226Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell Transplantation
Phase 2 · 3 location(s) · University Hospital, Basel, Switzerland · NCT03805477The Efficacy and Safety of Desensitation Regimen for Patients With High Titers of Anti-HLA Antibodies Prior to Allo-HSCT
Phase 2 · 1 location(s) · Anhui Provincial Hospital · NCT06362967211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymph
Phase 1/Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT03128034CD7 CAR-T Bridging to alloHSCT for Severe Aplastic Anemia
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT06633328The MedMemos Study: Promoting Adherence to Medications in Pediatric Bone Marrow Transplant Patients
NA · 1 location(s) · Nationwide Children's Hospital · NCT07718204Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies
Phase 2 · 3 location(s) · Hackensack Meridian Health · NCT07214688Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation
Phase 2 · 2 location(s) · Istituto Clinico Humanitas · NCT06892223Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant
Phase 1 · 2 location(s) · City of Hope Medical Center · NCT06543381Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain Reaction
Phase N/A · 1 location(s) · Peking University People's Hospital · NCT06211166Fecal Microbiota Transplantation for Steroid-Refractory Acute GI GVHD
Phase 2 · 1 location(s) · Chang Gung Memorial Hospital · NCT07364617VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCT
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06447090Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the RESTART Trial
NA · 2 location(s) · Dana-Farber Cancer Institute · NCT05236062Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
Phase 2 · 1 location(s) · Henry Ford Health System · NCT03850418Effect of Stem Cell Infusion Time on aGVHD in Patients With Nonmalignant Hematologic Diseases
Phase 3 · 6 location(s) · Anhui Provincial Hospital · NCT06294691Effect of Rifaximin on Gut Bacterial Flora Post Stem Cell Transplant in Patients With Acute Leukemia
Phase 2 · 1 location(s) · Tata Memorial Centre · NCT06058572Burden of Cytomegalovirus Reactivation in Pediatric Patients After Allogeneic Hematopoietic Stem Cell Transplantation
Phase N/A · 5 location(s) · MSD Italia S.r.l. · NCT06916195
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.